Translate Bio to Present at Upcoming Investor Conferences
November 13 2019 - 7:30AM
Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA
(mRNA) therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced that Company management will
present at the following investor conferences:
- Stifel 2019 Healthcare Conference, Tuesday, November 19, 2019,
9:45 a.m. ET, New York, NY
- Jefferies London Healthcare Conference, November 21, 2019,
10:00 a.m. GMT, London, England
- Evercore ISI 2nd Annual HealthCONx Conference, December 4,
2019, 3:30 p.m. ET, Boston, MA
A live webcast of the presentations will be accessible through
the “Events and Presentations” page of the Company's website at
investors.translate.bio. A replay of the webcast will be archived
on the Translate Bio’s website for 30 days following the
presentation.
About Translate BioTranslate Bio is a
clinical-stage mRNA therapeutics company developing a new class of
potentially transformative medicines to treat diseases caused by
protein or gene dysfunction. The Company’s MRT platform is designed
to develop product candidates that deliver mRNA carrying
instructions to produce intracellular, transmembrane and secreted
proteins for therapeutic benefit. Translate Bio is primarily
focused on applying its MRT platform to treat pulmonary diseases
caused by insufficient protein production or where production of
proteins can modify disease. The Company also believes its
technology is applicable to a broad range of diseases, including
diseases that affect the liver, eye and central nervous system.
Additionally, the MRT platform may be applied to various classes of
treatments, such as therapeutic antibodies or vaccines in areas
such as infectious disease and oncology. Translate Bio’s lead
program is being developed as a treatment for cystic fibrosis (CF)
and is in an ongoing Phase 1/2 clinical trial. For more information
about the Company, please visit www.translate.bio or on Twitter at
@TranslateBio.
Contact for Translate Bio
Investors |
|
Media |
Teri Dahlman |
|
Maura Gavaghan |
tdahlman@translate.bio |
|
mgavaghan@translate.bio |
857-242-7792 |
|
857-242-7789 |
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024